Otic agents and/or other pharmaceutical agents disclosed herein are optionally incorporated within controlled release particles, lipid complexes, liposomes, nanoparticles, microspheres, nanocapsules or other agents which enhance or facilitate the localized delivery of the otic agent
To attain this goal, biomimetic scaffold materials, different stem cell types, and optimized differentiation protocols have been developed [9-11]
Because stem cells can regenerate tissue, they are ideal for cases where there is significant tissue damage or degeneration
The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines
The Immunogenicity Argument The FDAs primary objection to DSIP is the risk of immunogenicity
Some marine food products are recommended by many medical authorities worldwide [84]